atorvastatin has been researched along with Diabetes Mellitus, Type 1 in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 16 (48.48) | 29.6817 |
| 2010's | 16 (48.48) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maraqa, AD | 1 |
| Chattipakorn, K; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Lungaphin, A; Pongchaidecha, A; Pratchayasakul, W; Satjaritanun, P; Thongnak, LO | 1 |
| de Zeeuw, D; Heerspink, HJL; Idzerda, NMA; Parving, HH; Pena, MJ | 1 |
| Adamson, U; Jörneskog, G; Lins, PE; Mobarrez, F; Tehrani, S; Wallén, HN | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Casiano, H; Crespo, MJ; Cruz, N; Hernandez, C; Quidgley, J; Rivera, K; Torres, H | 1 |
| Bao, W; Betteridge, DJ; Buchan, AP; Colhoun, H; DeMicco, DA; Durrington, PN; Fuller, JH; Hawa, MI; Hitman, GA; Leslie, RD; Neil, HA; Ola, T; Wun, CC | 1 |
| Doerfer, J; Grulich-Henn, J; Grünert, SC; Holder, M; Krebs, A; Lichte, K; Schmidt-Trucksäss, A; Schwab, KO; Stier, B; Winkler, K; Wöhrl, J | 1 |
| Canas, JA; Caulfield, MP; Damaso, LC; Gidding, SS; Hossain, J; Mauras, N; Ross, JL; Sikes, KM; Taboada, MV | 1 |
| Bergen, K; Brismar, K; Tehrani, S | 1 |
| Doerfer, J; Grulich-Henn, J; Hecker, W; Holder, M; Krause, A; Krebs, A; Lichte, K; Schmidt-Trucksaess, A; Schwab, KO; Winkler, K | 1 |
| Bantly, A; Hamamdzic, D; Mohler, ER; Moore, J; Parmacek, M; Putt, M; Rader, DJ; Shi, Y; Wilensky, RL; Yoder, M; Zhang, L | 1 |
| Haller, MJ; Pepine, C; Samyn, MM; Shuster, JJ; Silverstein, JH; Stein, JM; Theriaque, D | 1 |
| Adamson, U; Antovic, A; Henriksson, P; Jörneskog, G; Lins, PE; Mobarrez, F; Santesson, P; Tehrani, S; Wallén, NH | 1 |
| Heinemann, L; Heise, T; Herder, C; Koenig, W; Kolb, H; Martin, S; Schloot, NC | 1 |
| Eeg-Olofsson, K; Eliasson, B; Gudbjörnsdóttir, S; Jonasson, JM; Miftaraj, M; Sundell, KA; Svensson, AM | 1 |
| Heinemann, L; Heise, T; Herder, C; Koenig, W; Kolb, H; Martin, S; Roden, M; Schloot, NC; Simon, MC; Strom, A | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Barshes, NR; Goodpastor, SE; Goss, JA | 1 |
| Caselli, A; Economides, PA; Horton, ES; Khaodhiar, L; Tiani, E; Veves, A | 1 |
| De Leeuw, I; Manuel-Y-Keenoy, B; Van Gaal, L; Vertommen, J; Vinckx, M | 1 |
| Chan, DC; Dogra, GK; Stanton, K; Watts, GF | 1 |
| Blanco-Vaca, F; Calpe-Berdiel, L; Carrillo, J; Mauricio, D; Palomer, X; Pastor, X; Verdaguer, J | 1 |
| Bell, DS; Vaughan, TB | 1 |
| Brumeanu, TD; Casares, S; Goldstein, R | 1 |
| Barone, F; Lozanoska-Ochser, B; Peakman, M; Pitzalis, C | 1 |
| Kaupper, T; Walter, M; Ziegler, AG | 1 |
| Dhayat, N; Dhayat, S; Du, J; Hilfiker-Kleiner, D; Laufs, U; Noutsias, M; Riad, A; Schultheiss, HP; Spillmann, F; Tschöpe, C; Van Linthout, S; Westermann, D | 1 |
| Cieslik, G; Fedak, D; Galicka-Latala, D; Konduracka, E; Naskalski, J; Piwowarska, W; Rostoff, P; Sieradzki, J | 1 |
| Bauersachs, J; Brandt, M; Closs, E; Daiber, A; Ertl, G; Förstermann, U; Münzel, T; Oelze, M; Thum, T; Wenzel, P; Xu, J; Zou, MH | 1 |
| Gänzer, H; Kirchmair, R; Patsch, JR; Sturm, W | 1 |
| Deanfield, JE; Donald, AE; Mullen, MJ; Thomson, H; Thorne, S; Wright, D | 1 |
3 review(s) available for atorvastatin and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors.
Topics: Animals; Antigen-Presenting Cells; Atorvastatin; Autoimmune Diseases; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Down-Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; T-Lymphocytes | 2006 |
[Immunointervention in newly diagnosed type 1 diabetes].
Topics: Antibodies, Monoclonal; Atorvastatin; Autoimmune Diseases; Diabetes Mellitus, Type 1; Heptanoic Acids; Humans; Immunosuppressive Agents; Insulin-Secreting Cells; Prediabetic State; Pyrroles | 2006 |
[Statins in diabetic hyperlipidemia].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles; Risk Factors; Triglycerides | 1999 |
18 trial(s) available for atorvastatin and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials.
Topics: Atorvastatin; Cholesterol; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Function Tests; Male; Middle Aged; Proteinuria; Rosuvastatin Calcium | 2019 |
Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes.
Topics: Administration, Cutaneous; Adult; Atorvastatin; Biomarkers; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Endothelium, Vascular; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iontophoresis; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pyrroles; Risk Factors; Skin; Sweden; Time Factors; Treatment Outcome; Vasodilator Agents | 2013 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes.
Topics: Adult; Age of Onset; Aged; Anticholesteremic Agents; Atorvastatin; Autoantibodies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucose Intolerance; Glutamate Decarboxylase; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Phenotype; Prevalence; Prospective Studies; Pyrroles; Risk Factors | 2014 |
Decreased levels of homoarginine and asymmetric dimethylarginine in children with type 1 diabetes: associations with cardiovascular risk factors but no effect by atorvastin.
Topics: Adolescent; Anticholesteremic Agents; Arginine; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Glycated Hemoglobin; Heptanoic Acids; Homoarginine; Humans; Lipids; Male; Pilot Projects; Pyrroles; Risk Factors; Treatment Outcome | 2015 |
A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.
Topics: Adolescent; Atorvastatin; Child; Cholesterol, LDL; Combined Modality Therapy; Diabetes Mellitus, Type 1; Diet, Diabetic; Diet, Fat-Restricted; Double-Blind Method; Drug Monitoring; Exercise; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Pilot Projects; Pyrroles | 2015 |
High-dose atorvastatin is associated with lower IGF-1 levels in patients with type 1 diabetes.
Topics: Acetylcholine; Adult; Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Iontophoresis; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Nitroprusside; Risk Factors; Skin; Vasodilation; Vasodilator Agents | 2016 |
Lipoprotein-associated phospholipase A2 activity and low-density lipoprotein subfractions after a 2-year treatment with atorvastatin in adolescents with type 1 diabetes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adolescent; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Humans; Immunoenzyme Techniques; Male; Prognosis; Prospective Studies | 2016 |
Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Child; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Patient Compliance; Peripheral Vascular Diseases; Pilot Projects; Placebos; Pyrroles; Radial Artery; Vascular Resistance; Young Adult | 2009 |
Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Platelets; C-Reactive Protein; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Dyslipidemias; Fibrin; Fibrinolytic Agents; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin beta3; Middle Aged; P-Selectin; Plasminogen Activator Inhibitor 1; Pyrroles; Sweden; Thrombin; Thromboplastin; Thrombosis; Time Factors; Treatment Outcome | 2010 |
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.
Topics: Adult; Atorvastatin; C-Peptide; Diabetes Mellitus, Type 1; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Insulin-Secreting Cells; Lipids; Male; Pyrroles; Treatment Outcome | 2011 |
Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial).
Topics: Adolescent; Adult; Age of Onset; Atorvastatin; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 1; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin-Secreting Cells; Male; Pyrroles; Young Adult | 2012 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes.
Topics: Adult; Atorvastatin; Biomarkers; Brachial Artery; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Microcirculation; Middle Aged; Nitroglycerin; Pyrroles; Regional Blood Flow; Risk Factors; Skin; Vasodilation; Vasodilator Agents | 2004 |
Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin.
Topics: Adult; Aged; alpha-Tocopherol; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 1; Dietary Supplements; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipoproteins; Male; Middle Aged; Pyrroles | 2004 |
Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria.
Topics: Adolescent; Adult; Aged; Albuminuria; Apolipoproteins B; Atorvastatin; Brachial Artery; Cholesterol, LDL; Cross-Over Studies; Cyclic GMP; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitroglycerin; Pyrroles; Regional Blood Flow; Statistics, Nonparametric; Vasodilation; Vasodilator Agents | 2005 |
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Topics: Adult; Atorvastatin; Brachial Artery; Coronary Artery Disease; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Vasodilation; von Willebrand Factor | 2008 |
Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study.
Topics: Adolescent; Adult; Arginine; Atorvastatin; Diabetes Mellitus, Type 1; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Vasodilation | 2000 |
12 other study(ies) available for atorvastatin and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Effect of atorvastatin on interleukins and prostaglandin E2 in the kidney of type 1 diabetic rats.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dinoprostone; Interleukin-1; Kidney; Male; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tumor Necrosis Factor-alpha | 2016 |
Atorvastatin and insulin equally mitigate brain pathology in diabetic rats.
Topics: Animals; Atorvastatin; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Hypoglycemic Agents; Insulin; Male; Oxidative Stress; Rats; Rats, Wistar | 2018 |
Daily administration of atorvastatin and simvastatin for one week improves cardiac function in type 1 diabetic rats.
Topics: Animals; Atorvastatin; Blood Glucose; Cardiac Output; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Administration Schedule; Heart; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Ventricular Function, Left | 2014 |
Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Atorvastatin; Azetidines; Bone Marrow Cells; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Endothelial Cells; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stem Cells; Swine; Vasodilation | 2009 |
Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).
Topics: Adolescent; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Area Under Curve; Atorvastatin; Biomarkers; Cardiomyopathies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multicenter Studies as Topic; Puberty; Pyrroles; Quinapril; Randomized Controlled Trials as Topic; Research Design; Risk; Tetrahydroisoquinolines | 2009 |
Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register.
Topics: Adolescent; Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Registries; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Sweden; Treatment Outcome | 2011 |
Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient.
Topics: Adult; Atorvastatin; Diabetes Mellitus, Type 1; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Islets of Langerhans Transplantation; Pyrroles; Sirolimus | 2003 |
Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes.
Topics: Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 1; Female; Food-Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Pyrroles | 2005 |
Statin neuropathy masquerading as diabetic autoimmune polyneuropathy.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Autoimmunity; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Female; Heptanoic Acids; Humans; Pyrroles; Restless Legs Syndrome | 2005 |
Atorvastatin fails to prevent the development of autoimmune diabetes despite inhibition of pathogenic beta-cell-specific CD8 T-cells.
Topics: Animals; Atorvastatin; CD8-Positive T-Lymphocytes; Diabetes Mellitus, Type 1; Female; Heptanoic Acids; Histocompatibility Antigens Class II; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukin-10; Interleukin-4; Mice; Mice, Inbred NOD; Pyrroles | 2006 |
Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Heart; Heptanoic Acids; Inflammation; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left; Ventricular Function, Left | 2007 |
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus.
Topics: Animals; Atorvastatin; Biopterins; Body Weight; Cell Adhesion Molecules; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Disease Models, Animal; Endothelium, Vascular; Enzyme Activation; GTP Cyclohydrolase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Oxidoreductases; Male; Microfilament Proteins; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphoproteins; Pyrroles; Rats; Rats, Wistar; Stem Cells; Tetrahydrofolate Dehydrogenase; Vasodilation | 2008 |